Molecular prognostic markers in advanced gastric cancer: Correlative study in the Japan Clinical Oncology Group trial JCOG9912.

Yamada, Yuhei; Mizusawa, Junki; Takashima, Atsuo; Nakamura, K.; Tsuji, Yasushi; Suzuki, Yutaka; Amagai, Kenji; Yamagata, Kenji; Konishi, Kazuo; Yoshino, Tadashi; Denda, Tadamichi; Koizumi, Wasaburo; Ohkawa, S.; Kawai, Hiroki; Kojima, Hideyuki; Nishizaki, H.; Nishina, Takuya; Tsuji, Akihito; Fukuda, Haruhiko; Boku, Narikazu

doi:10.1200/jco.2011.29.15_suppl.4021

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, pretreatment tumor tissue was available from 365 of 704 (52%) patients enrolled in JCOG9912 trial. It was suggested that dihydropyrimidine dehydrogenase might be a selective marker between CPT-11 plus CDDP and S-1 (23) and excision repair cross-complementing group 1 may be an independent prognostic factor for overall survival after first-line treatment of advanced gastric cancer (24).…”

Section: Translational Researchmentioning

confidence: 99%

“…GIOSG challenged to a translational research to find predictive marker for chemotherapy effects using the archived tissues of the patients enrolled to JCOG9001 (21), 9205 (22) and 9912 (23,24). The methods of evaluating chemosensitivity-related factors were initially limited to immunohistochemistry using formalin-fixed samples in JCOG9001 and 9205, and recently have progressed to lasercaptured microdissection and real-time RT -PCR in JCOG9912.…”

Section: Translational Researchmentioning

confidence: 99%

“…In the twenty-first century, GIOSG challenged to difficult clinical trials [JCOG0106 (14) and 0407 (15)] for gastric cancer patients with severe peritoneal metastasis, who are usually excluded from clinical trials especially for new drug approval, meaning that new standard treatment, including new agents, can hardly be applied to these patients. Along with these clinical trials, GIOSG has been continuing to conduct translational researches to find predictive marker for chemotherapy effects using the archived tissues of the patients enrolled to JCOG9001 (21), 9205 (22) and 9912 (23,24). Recently, GIOSG has expanded its activity for colorectal cancer [JCOG9703 (9) …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Past and Present Achievements, and Future Direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG)

Boku

2011

Japanese Journal of Clinical Oncology

Self Cite

View full text Add to dashboard Cite

Initially, Gastrointestinal Study Group in Japan Clinical Oncology Group (GIOSG/JCOG) focused on gastric cancer. In 1980s, fluoropyrimidine, cisplatin and mitomycin C were key drugs. A randomized Phase II trial (JCOG8501) comparing futrafur plus mitomycin C and uracil plus futrafur and mitomycin C showed a higher response rate of uracil plus futrafur and mitomycin C than futrafur plus mitomycin C. From the results of two Phase II trials of etoposide, adriamycin and cisplatin, and cisplatin plus 5-fluorouracil, uracil plus futrafur and mitomycin C and cisplatin plus 5-fluorouracil were adopted for the test arms of the Phase III trial (JCOG9205) comparing with continuous infusion of 5-fluorouracil as a control arm. Neither cisplatin plus 5-fluorouracil nor uracil plus futrafur and mitomycin C showed a survival benefit over continuous infusion of 5-fluorouracil. In late 1990s, new agents, irinotecan and S-1, were developed for gastric cancer in Japan. GIOSG conducted a Phase III trial (JCOG9912) investigating superiority of irinotecan plus cisplatin and non-inferiority of monotherapy with S-1 compared with continuous infusion of 5-fluorouracil, and S-1 succeeded in showing non-inferiority. Then, SPIRITS trial showed a survival benefit of S-1 plus cisplatin over S-1, resulting in the establishment of a standard care for advanced gastric cancer in Japan. GIOSG have merged with Gastric Cancer Study Group as the Stomach Cancer Study Group (SCSG) from 2011. Recent progress in the development of new drugs has been remarkable. From the point of the roles shared with many other study groups for clinical trials, including registration trials of new drugs conducted by pharmaceutical companies, SCSG should recognize its role and conduct clinical trials with high quality for establishing new standard treatment.

show abstract

Section: Translational Researchmentioning

confidence: 99%

Section: Translational Researchmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Past and Present Achievements, and Future Direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG)

Boku

2011

Japanese Journal of Clinical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Blue Copper Proteins: A rigid machine for efficient electron transfer, a flexible device for metal uptake

Pérez-Henarejos

Alcaraz²,

Donaire

2015

Archives of Biochemistry and Biophysics

View full text Add to dashboard Cite

Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion

et al. 2016

View full text Add to dashboard Cite

In lung cancer, the Epidermal Growth Factor Receptor (EGFR) is one of the main targets for clinical management of this disease. The effectiveness of therapies toward this receptor has already been linked to the expression of integrin receptor subunit β1 in NSCLC A549 cells. In this work we demonstrate that azurin, an anticancer therapeutic protein originated from bacterial cells, controls the levels of integrin β1 and its appropriate membrane localization, impairing the intracellular signaling cascades downstream these receptors and the invasiveness of cells. We show evidences that azurin when combined with gefitinib and erlotinib, tyrosine kinase inhibitors which targets specifically the EGFR, enhances the sensitivity of these lung cancer cells to these molecules. The broad effect of azurin at the cell surface level was examined by Atomic Force Microscopy. The Young 's module (E) shows that the stiffness of A549 lung cancer cells decreased with exposure to azurin and also gefitinib, suggesting that the alterations in the membrane properties may be the basis of the broad anticancer activity of this protein. Overall, these results show that azurin may be relevant as an adjuvant to improve the effects of other anticancer agents already in clinical use, to which patients often develop resistance hampering its full therapeutic response.

show abstract

Molecular prognostic markers in advanced gastric cancer: Correlative study in the Japan Clinical Oncology Group trial JCOG9912.

Cited by 4 publications

References 0 publications

Past and Present Achievements, and Future Direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG)

Past and Present Achievements, and Future Direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG)

Blue Copper Proteins: A rigid machine for efficient electron transfer, a flexible device for metal uptake

Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion

Contact Info

Product

Resources

About